PhD Scientific Days 2023

Clinical Medicine - Posters A

Immune Checkpoint Inhibitors and Progression of Atherosclerosis Among Patients with Lung Cancer

Előadó neve

Dr. Drobni, Zsofia, PhD

Neptun code

yw3yd2

Előadó munkahelye

Semmelweis University

Előadó telefonszáma

+36206701227

Előadó e-mail címe

zsofi.drobni@gmail.com

Az előadás címe

Immune Checkpoint Inhibitors and Progression of Atherosclerosis Among Patients with Lung Cancer

Szerző(k) neve és munkahelye

Zsofia D. Drobni, MD, PhD1,2, Dorottya Balla MD1, Vencel Juhasz MD1, Carlos A. Gongora, MD2, Giselle A. Suero-Abreu, MD, PhD2, Julia Karady, MD1,2, Nicholas J. Leeper, MD, PhD3, Bela Merkely, MD, PhD1, Pal Maurovich-Horvat MD, PhD, MPH4, Borek Foldyna, MD2, Tomas G. Neilan, MD, MPH2,5

1, Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
2, Heart and Vascular Center, Semmelweis University, Budapest, Hungary
3, Department of Surgery Stanford University, Stanford, California
4, MTA-SE Cardiovascular Imaging Research Group, Medical Imaging Centre, Semmelweis University, Budapest, Hungary
5, Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Bemutatás módja

Poszter

Szekció

Clinical Medicine - Posters A

Language of the presentation

English

Preferred session

Clinical Medicine

Összefoglaló szövege

Introduction: Patients with lung cancer face a heightened risk of atherosclerosis-related cardiovascular events. Despite robust scientific plausibility, no clinical data are testing the effect of immune checkpoint inhibitors (ICI) on the progression of atherosclerosis in lung cancer.
Aims: We aimed to test whether ICIs were associated with accelerated atherosclerosis in patients with lung cancer.

Methods: In this case-control (2:1 matched by age and gender) study (NCT04430712), total, non-calcified, and calcified plaque volumes in the thoracic aorta were assessed on serial contrast-enhanced chest CTs. Univariate and multivariate rank-based estimation regression models were built to estimate the effect of ICI therapy on plaque progression in 40 cases (ICI) and 20 controls (non-ICI).

Results: The median age of patients was 66 (IQR:58-69) years, 50% were female. There were no differences in plaque volumes at baseline and the groups were of similar cardiovascular risk. The yearly progression rate was 7 times greater with an ICI as compared to controls for non-calcified plaque volume (11.2% vs. 1.6% per-year, P=0.001), while the progression of calcified plaque volume was greater among the controls (2% vs. 25% per-year, P=0.017). In a multivariate model, including cardiovascular risk factors, the use of an ICI was associated with a greater progression of non-calcified plaque volume. Plaque progression was also greater in those treated with combination ICI therapy.

Conclusions: ICI therapy was associated with more non-calcified plaque progression. These data support the need for studies identifying the mechanisms leading to plaque progression among patients treated with ICI.

Funding:
Dr. Drobni was supported by the ÚNKP-22-4-II-SE new national excellence program of the Ministry for Innovation and Technology from the national research, development, and innovation fund source. Dr. Neilan is supported by a gift from A. Curt Greer and Pamela Kohlberg, the Michael and Kathryn Park Endowed Chair in Cardiology, and a Hassenfeld Scholar Award. Dr. Neilan is also supported by grants from the National Institutes of Health/National Heart, Lung, and Blood Institute grants (R01HL130539, R01HL137562, R01HL159187, K24HL150238).

Email: zsofi.drobni@gmail.com, drobni.zsofia@semmelweis.hu

University and Doctoral School

Semmelweis University, Doctoral School of Theoretical and Translational Medicine

Supervisor

none

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

2749

Start

12:18

End

12:23

Authors (legacy)

Zsofia D. Drobni, MD, PhD1,2, Dorottya Balla MD1, Vencel Juhasz MD1, Carlos A. Gongora, MD2, Giselle A. Suero-Abreu, MD, PhD2, Julia Karady, MD1,2, Nicholas J. Leeper, MD, PhD3, Bela Merkely, MD, PhD1, Pal Maurovich-Horvat MD, PhD, MPH4, Borek Foldyna, MD2, Tomas G. Neilan, MD, MPH2,5

1, Cardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
2, Heart and Vascular Center, Semmelweis University, Budapest, Hungary
3, Department of Surgery Stanford University, Stanford, California
4, MTA-SE Cardiovascular Imaging Research Group, Medical Imaging Centre, Semmelweis University, Budapest, Hungary
5, Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts